Addex Therapeutics Reports Significant Loss Amid Financial Challenges

Addex Therapeutics Ltd (ADR) ( (ADXN) ) has released its Q2 earnings. Here is a breakdown of the information Addex Therapeutics Ltd (ADR) presented to its investors.

Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company based in Switzerland, focusing on developing novel small molecule allosteric modulators for neurological disorders. The company operates in the pharmaceutical industry and is known for its innovative approach to drug discovery and development. In its latest half-year interim report for 2025, Addex Therapeutics reported a significant net loss, highlighting the financial challenges it faces. The company recorded a net loss of CHF 3.3 million for the first half of 2025, compared to a net profit of CHF 9.8 million in the same period of 2024, primarily due to the absence of revenue from contracts with customers and increased operating costs. The report also noted a decrease in cash and cash equivalents, which stood at CHF 2.3 million as of June 30, 2025, down from CHF 3.3 million at the end of 2024. Despite these challenges, Addex Therapeutics continues to focus on its core research and development activities, with operating costs primarily driven by these efforts. The company’s management remains committed to securing additional funding to support its operations and future growth. Looking ahead, Addex Therapeutics aims to continue its strategic focus on developing its portfolio of allosteric modulators, while actively seeking collaborations and partnerships to enhance its financial stability and operational capabilities.